MedTrace Logo

Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib

NCT00812175 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3371

Last updated 2016-10-17

No results posted yet for this study

Summary

In this international non-interventional study safety and clinical data concerning the treatment of patients suffering from Hepatocellular Carcinoma (HCC) will be collected.

Conditions

  • Carcinoma, Hepatocellular

Interventions

DRUG

Sorafenib (Nexavar, BAY43-9006)

Systemic oral therapy according to product information

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United States
  • Canada
  • China
  • Colombia
  • Croatia
  • Czechia
  • Finland
  • France
  • Greece
  • Hong Kong
  • Hungary
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Kazakhstan
  • Libya
  • Malaysia
  • Mexico
  • Norway
  • Pakistan
  • Philippines
  • Portugal
  • Qatar
  • Romania
  • Russia
  • Singapore
  • Slovakia
  • South Korea
  • Spain
  • Sweden
  • Syria
  • Thailand
  • Ukraine
  • United Arab Emirates
  • Uruguay
  • Venezuela
  • Vietnam

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00812175 on ClinicalTrials.gov